1. Jab1/Cops5: a promising target for cancer diagnosis and therapy

   • Chunjue Yuan
   • Dong Wang
   • Yunbao Pan

   Review Article 21 May 2021 Pages: 1159 - 1169

   

2. Symptoms and signs of parotid tumors and their value for diagnosis and prognosis: a 20-year review at a single institution

   • Yuko Inaka
   • Ryo Kawata
   • Yusuke Kikuoka

   Original Article 07 April 2021 Pages: 1170 - 1178

   

3. Predictors of the need for prophylactic percutaneous endoscopic gastrostomy in head and neck cancer patients treated with concurrent chemoradiotherapy

   • Satoshi Kano
   • Nayuta Tsushima
   • Akihiro Homma

   Original Article 04 June 2021 Pages: 1179 - 1187

   

4. Clinical impact of weekly paclitaxel plus cetuximab is comparable to the EXTREME regimen for recurrent/metastatic head and neck squamous cell carcinoma

   • Risa Motai
   • Michi Sawabe
   • Nobuhiro Hanai

   Original Article 05 April 2021 Pages: 1188 - 1195

   

5. Otorhinolaryngologists/head and neck surgeons’ knowledge, attitudes, and practices regarding fertility preservation in young cancer patients treated with chemotherapy: an anonymous questionnaire survey

   • Naoki Akisada
   • Nobuya Monden
   • Kazunori Nishizaki

   Original Article 06 May 2021 Pages: 1196 - 1202

   

6. Epidemiology and prognosis of lymphoepithelioma-like carcinoma: a comprehensive analysis of surveillance, epidemiology, and end results (SEER) database

   • Wei-xiang Qi
   • Shengguang Zhao
   • Jiayi Chen

   Original Article 12 April 2021 Pages: 1203 - 1211

   

7. Efficacy and safety of ¹⁸⁸Re-HEDP in lung cancer patients with bone metastases: a randomized, multicenter, multiple-dose phase IIa study

   • Ping Chen
   • Jun Li
   • Xingdang Liu

   Original Article 13 April 2021 Pages: 1212 - 1220

   

8. Are all ALK variants created equal? Clinicopathologic features and outcomes: a propensity-matched study

   • Ullas Batra
   • Mansi Sharma
   • Anurag Mehta

   Original Article 12 April 2021 Pages: 1221 - 1228

   

9. Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19)

   • Kenjiro Aogi
   • Kenichi Watanabe
   • Shinji Ohno

   Original Article Open access 23 April 2021 Pages: 1229 - 1236

   

10. Correction to: Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19)

    • Kenjiro Aogi
    • Kenichi Watanabe
    • Shinji Ohno

    Correction Open access 27 May 2021 Pages: 1237 - 1237

11. Safety and efficacy of panitumumab in combination with trifluridine/tipiracil for pre-treated patients with unresectable, metastatic colorectal cancer with wild-type RAS: The phase 1/2 APOLLON study

    • Takeshi Kato
    • Yoshinori Kagawa
    • Kensei Yamaguchi

    Original Article Open access 29 April 2021 Pages: 1238 - 1247

    

12. Benefit of intensive chemotherapy for elderly patients aged 80 years or older with metastatic colorectal cancer: a state-wide multicenter cohort study

    • Yujiro Nakayama
    • Hidetaka Kawamura
    • Shinichi Konno

    Original Article 05 June 2021 Pages: 1248 - 1256

    

13. Association of albumin–bilirubin score in patients with colorectal cancer receiving later-line chemotherapy with regorafenib

    • Daichi Watanabe
    • Hironori Fujii
    • Akio Suzuki

    Original Article 11 April 2021 Pages: 1257 - 1263

    

14. The carcinoembryonic antigen ratio is a potential predictor of survival in recurrent colorectal cancer

    • Yumi Suzuki
    • Atsushi Ogura
    • Tomoki Ebata

    Original Article 11 April 2021 Pages: 1264 - 1271

    

15. Comparison of prognostic impact between positive intraoperative peritoneal and lavage cytologies in colorectal cancer

    • Kentaro Sato
    • Ken Imaizumi
    • Kazuaki Nakanishi

    Original Article 12 April 2021 Pages: 1272 - 1284

    

16. Tumor budding as a predictive marker for 5-fluorouracil response in adjuvant-treated stage III colorectal cancer

    • Shintaro Akabane
    • Wataru Shimizu
    • Hideki Ohdan

    Original Article 21 April 2021 Pages: 1285 - 1292

    

17. The impact of cachexia and sarcopenia in elderly pancreatic cancer patients receiving palliative chemotherapy

    • Tsuyoshi Takeda
    • Takashi Sasaki
    • Naoki Sasahira

    Original Article 31 March 2021 Pages: 1293 - 1303

    

18. Computed tomography findings for predicting the future occurrence of pancreatic cancer: value of pancreatic volumetry

    • Yuki Kawaji
    • Takanori Yoshikawa
    • Masayuki Kitano

    Original Article 07 April 2021 Pages: 1304 - 1313

    

19. Docetaxel and carboplatin chemotherapy for treating patients with stage IVB or recurrent non-squamous cell carcinoma of the uterine cervix: a phase II study

    • Muneaki Shimada
    • Shinya Sato
    • Junzo Kigawa

    Original Article 07 April 2021 Pages: 1314 - 1321

    

20. Survival impact of adjuvant concurrent chemoradiotherapy after radical hysterectomy in FIGO stage IIIC1 cervical adenocarcinoma

    • Kazuhiro Suzuki
    • Shoji Nagao
    • Satoshi Yamaguchi

    Original Article 06 April 2021 Pages: 1322 - 1329

    

21. Prognostic impact of the subclassification of Müllerian cancer stage IV in the FIGO 2014 staging system with a focus of extra-abdominal lymph node metastases

    • Masafumi Yasunaga
    • Hideaki Yahata
    • Kiyoko Kato

    Original Article 30 March 2021 Pages: 1330 - 1335

    

22. Validation of tissue factor pathway inhibitor 2 as a specific biomarker for preoperative prediction of clear cell carcinoma of the ovary

    • Etsuko Miyagi
    • Noriaki Arakawa
    • Hiroshi Kobayashi

    Original Article Open access 19 May 2021 Pages: 1336 - 1344

    

23. Laboratory prognostic score for predicting 14-day mortality in terminally ill patients with gynecologic malignancy

    • Kazuma Onishi
    • Natsuko Kawai
    • Norihiro Yuasa

    Original Article 09 May 2021 Pages: 1345 - 1352